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We	 rapidly	 identified	 extended-spectrum	 β-lactamase	
(ESBL)	producers	prospectively	among	245	gram-negative	
bacilli–positive	 cultured	blood	 specimens	using	 the	Rapid	
ESBL	Nordmann/Dortet/Poirel	test	and	direct	bacterial	iden-
tification	 using	matrix-assisted	 laser	 desorption	 ionization	
time-of-flight	 mass	 spectrometry.	 This	 combination	 identi-
fied	ESBL-producing	Enterobacteriaceae	within	30	min	and	
had	high	predictive	values.
An essential parameter for improving the outcome of sepsis is early implementation of appropriate anti-
biotic therapy (1–5). Recently, using matrix-assisted la-
ser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry (MS) technology directly with blood 
cultures was found to help guide clinical management of 
bacteremia caused by gram-negative bacteria (GNB) (6). 
Resistance to broad-spectrum cephalosporins is spread-
ing rapidly among Enterobacteriaceae, mostly related to 
acquisition of extended-spectrum β-lactamases (ESBLs) 
(7). ESBL-producing Enterobacteriaceae (ESBL-E) are 
usually resistant to most b-lactams except cephamycins 
and carbapenems.
Using PCR-based molecular techniques on positive 
blood cultures has been proposed for rapid identification of 
ESBLs (8); however, trained personnel and expensive ma-
terial are required for their use. In addition, for the TEM- 
and SHV-type enzymes, detailed gene sequence analysis is 
required for differentiating narrow-spectrum β-lactamases 
from ESBLs.
Rapid identification of ESBL producers is possible by 
using the ESBL Nordmann/Dortet/Poirel (NDP) test (9), 
which is based on the biochemical detection of the hydro-
lysis of the b-lactam ring of cefotaxime (a broad-spectrum 
cephalosporin). Presence of these bacteria has previously 
been evaluated with cultured bacteria and with spiked 
blood cultures (9).
In this study, we evaluated the ESBL NDP test 
prospectively in clinical settings directly from blood 
cultures. Identification of the bacterial species was done 
concomitantly from blood cultures by using enhanced 
MALDI-TOF procedures.
The Study
During November 2012–May 2013, we studied a single 
blood culture positive for GNB from each of 245 patients 
hospitalized at the Bicêtre hospital, a 950-bed hospital lo-
cated in a suburb of Paris. Positivity of blood cultures was 
detected by using the BacT/Alert system (bioMérieux, La 
Balme-les-Grottes, France). After obtaining Gram stain re-
sults, we tested the blood cultures positive for GNB directly 
for 1) ESBL-E by using the ESBL NDP test, and 2) species 
identification by using the MALDI-TOF MS technique.
We adapted the protocol of the ESBL NDP test for de-
tection of the ESBL-E from blood cultures (9) (Online Tech-
nical Appendix, http://wwwnc.cdc.gov/EID/article/21/3/ 
14-1277-Techapp1.pdf). The detailed MALDI-TOF MS 
protocol using the VITEK MS system (bioMérieux) is de-
scribed in Detailed Methods in the Technical Appendix.
We performed antibiotic susceptibility testing (AST) 
by the disk diffusion method using bacterial colonies grown 
from blood cultures according to the Clinical Laboratory 
Standards Institute (CLSI) recommendations (10). The same 
MALDI-TOF technology and the API Gram negative Iden-
tification product (bioMérieux) were used for confirmatory 
identification of bacteria. AST results, obtained 48 h after 
blood cultures were identified as positive, were interpreted 
according to the CLSI breakpoints, as updated in 2014 (10). 
MIC of cefotaxime, ceftazidime, and cefepime were deter-
mined on Muller-Hinton (MH) agar and MH agar supple-
mented with 4 µg/mL of tazobactam (final concentration).
We used the double-disk synergy test (DDST) for the 
phenotypic detection of ESBL producers (11), according 
to the CLSI recommendations. For each sample, 1 disk 
contained cefotaxime, ceftazidime, or cefepime, and a 
second disk contained ticarcillin and clavulanate (10). The 
DDST was also performed on MH agar plates (bioMéri-
eux) containing cloxacillin (150 mg/L) to inhibit cephalo-
sporinase activity of natural producers of those inducible 
cephalosporinases. Because the DDST was performed in 
parallel to the AST, results were obtained 48 h later. The 
DDST was considered to be the reference standard for the 
detection of ESBL-E.
We also used molecular biology techniques to identify 
the ESBL genes. We used PCR to amplify DNA, which we 
then sequenced using bla
TEM
, bla
SHV
, and bla
CTX-M
 primers (9).
During the study, 245 blood specimens that were col-
lected from patients hospitalized in any unit of the hospital 
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were cultured and grew GNB (Table 1). The 245 cases of 
bacteremia were attributed to Enterobacteriaceae (211, 
86.1%), nonfermentative GNB (31, 12.7%), and anaero-
bic GNB (3, 1.2%) (Table 2). Three blood cultures (1.2%) 
were positive for 2 enterobacterial species (Table 2). Esch-
erichia coli was the predominant enterobacterial species 
(118/211, 55.9%); the next most prevalent were Klebsiella 
pneumoniae (37/211, 17.5%) and Enterobacter cloacae 
(20/211, 9.5%). Pseudomonas aeruginosa (24/31, 77.4%) 
was the predominant non-fermentative GNB (Table 2). 
Anaerobic GNB belonged to the Bacteroides fragilis group 
(Bacillus fragilis and Bacillus vulgatus).
We identified bacteria directly from blood culture us-
ing the MALDI-TOF technique for 237 (96.7%) isolates; 
results corresponded to bacterial identification after culture 
(Table 2). Salmonella spp. (n = 5) were correctly identi-
fied at the genus level (Table 1). For the 3 positive blood 
cultures that contained 2 enterobacterial species (Table 2), 
results were noninterpretable.
ESBL-E producers (n = 47) represented 22.3% of En-
terobacteriaceae. Among the 47 ESBL-E, 30 E. coli, 13 K. 
pneumoniae, 3 E. cloacae, and 1 Citrobacter freundii were 
identified from patients who were infected in the commu-
nity or the hospital (detailed data not shown) (Table 1; Ta-
ble 3, http://wwwnc.cdc.gov/EID/article/21/3/14-1277-T3.
htm). Most of the ESBLs were of the CTX-M-type (49/51, 
96.1%); CTX-M-15 was predominant (35/51, 68.6%). The 
proportion of ESBL producers were 35.1%, 25.4%, and 15% 
among K. pneumoniae, E. coli, and E. cloacae, respectively 
(Table 3). The ESBL NDP test perfectly identified the 47 
ESBL-E pathogens (Tables 1, 3). Accordingly, a 100% cor-
relation between intermediated susceptibility of resistance 
to cefotaxime and positivity of the ESBL NDP test was ob-
served, whereas this correlation was of 76.6% and 74.4%, 
respectively, when ceftazidime and cefepime susceptibility 
results were used for this same comparison (Table 3). The 
ESBL NDP test gave negative results for 164 specimens that 
were negative for ESBL-E (Table 2). The ESBL NDP test 
revealed a cefotaxime-hydrolyzing enzyme that was not in-
hibited by tazobactam for 1 K. pneumoniae isolate that pro-
duced an acquired cephalosporinase, 3 of the 5 E. cloacae 
that overproduced chromosome-encoded AmpC, and 2 Bac-
teroides spp. strains (data not shown).
The ESBL NDP test used with blood cultures had a 
sensitivity of 100% (95% CI: 92.4%–100%), a specific-
ity of 100% (95% CI: 97.7%–100%), a positive predic-
tive value of 100% (95% CI: 99.2%–100%) and a negative 
predictive value of 100% (95% CI: 97.8%–100%) for the 
detection of ESBL-E.
Conclusions
Detection of ESBLs that are the main source of cephalospo-
rin resistance in Enterobacteriaceae still relies on antibiotic 
susceptibility testing, results of which usually take 24–48 
h. We show that the ESBL NDP test directly performed on 
positive blood cultures is a reliable technique to identify ES-
BL-E within 30 min. Although these results are promising, 
they should be further confirmed in other countries where the 
prevalence and the epidemiology of ESBL-E might be differ-
ent. A strong correlation between intermediate susceptibility 
or resistance to cefotaxime and positivity of the ESBL NDP 
test was observed (Table 3). Similar correlation between 
resistance to cefotaxime and ESBL production in Entero-
bacteriaceae was obtained in the United States (12). A con-
comitant use of the Carba NP test (13) directly from blood 
culture will also identify carbapenemase producers (such as 
K. pneumoniae carbapenemase producers) that also confer 
clavulanic-acid–inhibited resistance to cephalosporins.
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Table 1. Origin of gram-negative	bacilli	identified	in	blood	samples	drawn	from	hospitalized	patients	and	cultured	by	using	rapid	
detection	methods	for bacterial	blood	cultures* 
Hospital	department 
No.	gram-
negative	bacilli 
No.	(%)	Enterobacteriaceae No.	(%)	
nonfermenting 
bacilli Total 
Escherichia 
coli Other 
ESBL-
negative 
ESBL-
positive 
Cardiology 5 4 (80) 2 (50) 2 (50) 4 (100) 0 1 (20) 
Digestive	surgery 9 8 (89) 6 (75) 2 (25) 6 (75) 2 (25) 1 (11) 
Orthopedic	surgery 3 3 (100) 2 (67) 1 (33) 3 (100) 0 0  
Endocrinology 2 2 (100) 0 2 (100) 2 (100) 0 0 
Gerontology 9 7 (78) 3 (43) 4 (57) 7 (100) 0 2 (22) 
Gynecology-obstetric 3 2 (67) 0 2 (100) 2 (100) 0 1 (33) 
Hepato-gastroenterology 20 18 (90) 8 (44) 10 (56) 15 (83) 3 (17) 2 (10) 
Emergency 40 37 (93) 30 (81) 7 (19) 32 (86) 5 (14) 3 (8) 
Infectious	diseases 28 25 (89) 16 (64) 9 (36) 17 (68) 8 (32) 3 (11) 
Nephrology 28 21 (75) 8 (38) 13 (62) 11 (52) 10 (48) 7 (25) 
Neurology 8 8 (100) 5 (63) 3 (38) 8 (100) 0 0 
Pediatric	unit 2 2 (100) 2 (100) 0 2 (100) 0 0 
Pneumology 4 3 (75) 2 (67) 1 (33) 2 (67) 1 (33) 1 (25) 
Intensive	care	unit 67 57 (85) 24 (42) 33 (58) 42 (74) 15 (26) 10 (15) 
Rhumatology 3 2 (67) 2 (100) 0 1 (50) 1 (50) 1 (33) 
Urology 14 12 (86) 8 (67) 4 (33) 10 (83) 2 (17) 2 (14) 
Total 245 211 (86) 118 (56) 93 (44) 164 (78) 47 (22) 34 (14) 
*ESBL,	extended spectrum β-lactamase. 
 
DISPATCHES
This inexpensive ESBL NDP test might be implement-
ed worldwide. It may optimize rapid choices of antibiotics 
for treating bloodstream infections. It may also contribute 
to avoidance of overuse of carbapenems. Finally, a rapid 
detection of ESBL-E coupled with bacterial species iden-
tification will enhance identification of ESBL in species 
likely to be the source of nosocomial outbreaks (K. pneu-
moniae, Enterobacter spp.) and facilitate implementation 
of a rapid strategy for containment (14).
This work was funded by grants from the INSERM (UMR914), 
France, and the University of Fribourg, Switzerland.
An international patent form for the ESBL NDP test has been 
filed on behalf of INSERM Transfert (Paris, France).
Dr. Dortet is an associate professor of medical microbiology, 
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